Jordan Daily – The Jordan Food and Drug Administration (JFDA) has suspended the approval of all natural products and dietary supplements containing Ashwagandha (Withania Somnifera) as of early August. This decision comes in response to increasing concerns over the misuse of these products and reports of adverse effects on the liver and digestive system.
JFDA Director General, Dr. Nizar Mhaidat, announced the suspension, which includes halting the circulation of Ashwagandha-containing products, suspending the registration of new products, and pausing the acceptance of new registration files.
The action follows the JFDA’s monitoring of product usage and the identification of unauthorized health claims in advertising, such as promoting Ashwagandha for weight loss, depression relief, immune boosting, heart disease prevention, cholesterol reduction, arthritis treatment, and high blood pressure management.
